[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Teknos TN, Cox C, Yoo S, Chepeha DB, Wolf GT, Bradford CR, Carey TE, Fisher SG: Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck; 2002 Nov;24(11):1004-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma.
  • PURPOSE: The purpose of this study was to determine whether serum vascular endothelial growth factor (s-VEGF) levels at the time of diagnosis correlate with any known tumor variables and overall survival in patients with advanced laryngeal squamous cell carcinoma.
  • Comparisons with a cohort of normal healthy controls were also performed to determine the potential usefulness of s-VEGF as a screening tool.
  • EXPERIMENTAL DESIGN: Serum from patients enrolled in the VA Laryngeal Cooperative Study #258 (n = 183), as well as normal healthy controls (n = 40) was used in this analysis.
  • RESULTS: The mean serum concentration of s-VEGF for the healthy control group was 47.83 +/- 0.13 pg/mL.
  • For all patients enrolled in the VA Cooperative Study, regardless of treatment group, the mean s-VEGF level was 317.22 +/- 25.46 pg/mL.
  • Those randomly assigned to the induction chemotherapy arm (n = 86) had a mean s-VEGF level of 319.22 +/- 42.11 pg/mL.
  • Serum VEGF levels were significantly elevated in patients with laryngeal carcinoma compared with healthy controls (p < .001).
  • The serum VEGF levels in each arm of the trial were also elevated versus the healthy controls (p < .001, surgery arm plus radiotherapy; p < .001, chemotherapy plus radiotherapy).
  • In a univariate analysis, elevated s-VEGF correlated with poor Karnofsky performance status for all patients with advanced laryngeal carcinoma (p < .008).
  • High s-VEGF levels also correlated with a poor performance score in patients on the chemotherapy arm of the VA Laryngeal Trial (p < .004).
  • Elevated s-VEGF levels in the surgical plus radiotherapy arm correlated with node-positive disease (p = .047) and supraglottic location of the tumor (p = .022).
  • In a multivariate analysis using all known tumor variables and s-VEGF levels, elevated s-VEGF levels and infiltrating growth pattern correlated with decreased survival for all evaluated patients with advanced laryngeal carcinoma (p = .065, and p = .018, respectively).
  • CONCLUSIONS: Serum VEGF levels are significantly elevated in patients with advanced laryngeal carcinoma versus healthy controls.
  • Elevated pretreatment s-VEGF levels tended to indicate a more aggressive disease state and a poorer overall survival in advanced laryngeal carcinoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / mortality. Endothelial Growth Factors / blood. Laryngeal Neoplasms / blood. Laryngeal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc.
  • (PMID = 12410536.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Endothelial Growth Factors
  •  go-up   go-down


2. Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A: Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol; 2010 Jun 1;28(16):2732-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To assess clinical and functional results of chemoradiotherapy for oropharyngeal cancer (OPC), utilizing intensity-modulated radiotherapy (IMRT) to spare the important swallowing structures to reduce post-therapy dysphagia.
  • PATIENTS AND METHODS: This was a prospective study of weekly chemotherapy (carboplatin dosed at one times the area under the curve [AUC, AUC 1] and paclitaxel 30 mg/m(2)) concurrent with IMRT aiming to spare noninvolved parts of the swallowing structures: pharyngeal constrictors, glottic and supraglottic larynx, and esophagus as well as the oral cavity and major salivary glands.
  • Swallowing was assessed by patient-reported Swallowing and Eating Domain scores, observer-rated scores, and videofluoroscopy (VF) before therapy and periodically after therapy through 2 years.
  • All measures of dysphagia worsened soon after therapy; observer-rated and patient-reported scores recovered over time, but VF scores did not.
  • At 1 year after therapy, observer-rated dysphagia was absent or minimal (scores 0 to 1) in all patients except four: one who was feeding-tube dependent and three who required soft diet.
  • From pretherapy to 12 months post-therapy, the Swallowing and Eating Domain scores worsened on average (+/- standard deviation) by 10 +/- 21 and 13 +/- 19, respectively (on scales of 0 to 100), and VF scores (on scale of 1 to 7) worsened from 2.9 +/- 1.5 (mild dysphagia) to 4.1 +/- 0.9 (mild/moderate dysphagia).
  • CONCLUSION: Chemoradiotherapy with IMRT aiming to reduce dysphagia can be performed safely for OPC and has high locoregional tumor control rates.

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):377-85 [18164838.001]
  • [Cites] Dysphagia. 2003 Winter;18(1):53-7 [12497197.001]
  • [Cites] Med Care. 2003 May;41(5):582-92 [12719681.001]
  • [Cites] Head Neck. 2003 Jun;25(6):432-7 [12784234.001]
  • [Cites] Head Neck. 2004 Apr;26(4):365-72 [15054740.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):28-42 [15093896.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):43-50 [15093897.001]
  • [Cites] Biometrics. 1982 Dec;38(4):963-74 [7168798.001]
  • [Cites] Head Neck. 1993 Nov-Dec;15(6):485-96 [8253555.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Oct;123(10):1125-32 [9339991.001]
  • [Cites] Head Neck. 1998 Jan;20(1):31-7 [9464950.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):615-9 [16027285.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3770-6 [18669465.001]
  • [Cites] Laryngoscope. 2008 Aug;118(8):1357-61 [18528311.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):617-22 [18793966.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8 [18468812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):737-46 [18486356.001]
  • [Cites] Semin Radiat Oncol. 2009 Jan;19(1):35-42 [19028344.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2008 Dec;117(12):919-24 [19140539.001]
  • [Cites] Radiother Oncol. 2009 Feb;90(2):189-95 [19167120.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1187-95 [19251090.001]
  • [Cites] Br J Radiol. 2009 Aug;82(980):675-80 [19332514.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):385-92 [19553033.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):462-7 [19577862.001]
  • [Cites] Head Neck. 2006 Jan;28(1):64-73 [16302193.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73 [15925451.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Mar;134(3):455-9 [16500444.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):298-305 [16524633.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Jun;134(6):916-22 [16730530.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2606-11 [16763272.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2636-43 [16763277.001]
  • [Cites] Support Care Cancer. 2006 Oct;14(10):988-98 [16794811.001]
  • [Cites] Radiother Oncol. 2006 Sep;80(3):302-6 [16890314.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):606-12 [17148999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):750-7 [17418971.001]
  • [Cites] Anticancer Res. 2007 May-Jun;27(3B):1663-8 [17595793.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98 [17560051.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):74-82 [17673322.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):64-73 [17714815.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2007 Nov;116(11):837-41 [18074669.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1289-95 [18086974.001]
  • [Cites] Head Neck. 2008 Feb;30(2):148-58 [17786992.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3964-71 [12351593.001]
  • (PMID = 20421546.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA059827; United States / NCI NIH HHS / CA / P50 CA097248; United States / NCI NIH HHS / CA / P01 CA59827; United States / NCI NIH HHS / CA / P50 CA97248
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2881852
  •  go-up   go-down


3. Hadjiiski L, Mukherji SK, Gujar SK, Sahiner B, Ibrahim M, Street E, Moyer J, Worden FP, Chan HP: Treatment response assessment of head and neck cancers on CT using computerized volume analysis. AJNR Am J Neuroradiol; 2010 Oct;31(9):1744-51
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment response assessment of head and neck cancers on CT using computerized volume analysis.
  • Our aim was to evaluate the potential usefulness of a computerized system for segmenting lesions in head and neck CT scans and for estimation of volume change of head and neck malignant tumors in response to treatment.
  • MATERIALS AND METHODS: CT scans from a pretreatment examination and a post 1-cycle chemotherapy examination of 34 patients with 34 head and neck primary-site cancers were collected.
  • The computerized system was developed in our laboratory.
  • The 34 tumors included tongue, tonsil, vallecula, supraglottic, epiglottic, and hard palate carcinomas.
  • RESULTS: The correlation between the automatic and manual estimates for both the pre- to post-treatment volume change and the percentage volume change for the 34 primary-site tumors was 0.95, with an average error of -2.4 ± 8.5% by automatic segmentation.
  • There was no substantial difference and specific trend in the automatic segmentation accuracy for the different types of primary head and neck tumors, indicating that the computerized segmentation performs relatively robustly for this application.
  • CONCLUSIONS: The tumor size change in response to treatment can be accurately estimated by the computerized segmentation system relative to radiologists' manual estimations for different types of head and neck tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiography. Imaging, Three-Dimensional / methods. Radiographic Image Interpretation, Computer-Assisted / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] AJR Am J Roentgenol. 2010 Apr;194(4):1083-9 [20308515.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2256-60 [15150551.001]
  • [Cites] Lancet. 1986 Feb 8;1(8476):307-10 [2868172.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):485-90 [2394626.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):281-7 [7673015.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1011-21 [9169807.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):711-9 [9336154.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):631-7 [10080608.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):755-65 [10386632.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2616-22 [15887218.001]
  • [Cites] Curr Opin Oncol. 2007 May;19(3):188-94 [17414635.001]
  • [Cites] Med Phys. 2007 Nov;34(11):4399-408 [18072505.001]
  • [Cites] Psychol Bull. 1979 Mar;86(2):420-8 [18839484.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • (PMID = 20595363.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093517
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS495353; NLM/ PMC3767432
  •  go-up   go-down


Advertisement
4. Wolf GT, Bradford CR, Urba S, Smith A, Eisbruch A, Chepeha DB, Teknos TN, Worden F, Dawson L, Terrell JE, Hogikyan ND: Immune reactivity does not predict chemotherapy response, organ preservation, or survival in advanced laryngeal cancer. Laryngoscope; 2002 Aug;112(8 Pt 1):1351-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune reactivity does not predict chemotherapy response, organ preservation, or survival in advanced laryngeal cancer.
  • OBJECTIVE: To determine whether pretreatment lymphocyte subpopulations correlate with tumor response to induction chemotherapy as part of an organ preservation treatment approach in patients with advanced laryngeal cancer.
  • STUDY DESIGN: A prospective clinical trial in patients with advanced laryngeal cancer was undertaken to determine whether the frequency of late salvage laryngectomy and overall survival could be improved using one cycle of neoadjuvant chemotherapy to select patients for organ preservation.
  • Pretreatment peripheral blood lymphocyte subpopulations for CD3, CD4, CD8, NK, and B cells were correlated with tumor response to induction chemotherapy, larynx preservation, and survival, to determine whether immune parameters could be useful in patient selection.
  • Most patients had supraglottic cancers (73%) and positive clinical nodes (51%).
  • Sixty-eight percent had greater than 50% tumor response after one cycle of induction chemotherapy and then received concurrent chemoradiation and two cycles of adjuvant chemotherapy.
  • Only 4 cases were late salvage resections (13-35 mo after treatment).
  • Fourteen cases were planned surgery after initial chemotherapy.
  • However, no significant differences in lymphocyte subpopulations were found among responders and nonresponders to chemotherapy.
  • CONCLUSIONS: One cycle of neoadjuvant chemotherapy was effective in selecting patients for organ preservation.
  • The regimen of definitive concurrent and adjuvant chemotherapy was associated with an unexpectedly high 2-year survival rate.
  • [MeSH-major] Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / immunology
  • [MeSH-minor] Chemotherapy, Adjuvant. Follow-Up Studies. Humans. Laryngectomy. Neoplasm Staging. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172244.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-46592-13
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


5. Yoshizaki T, Kondo S, Wakisaka N, Murono S, Kitagawa N, Tsuji A, Nakashima M, Sanada J, Matsui O: Concurrent intra-arterial chemotherapy and radiotherapy for advanced laryngeal cancer. Ann Otol Rhinol Laryngol; 2009 Mar;118(3):172-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent intra-arterial chemotherapy and radiotherapy for advanced laryngeal cancer.
  • METHODS: Forty-three patients with advanced laryngeal cancer were treated with 2 courses of intra-arterial cisplatin infusion (100 mg per body) during 40-Gy irradiation.
  • The patients who showed a greatly diminished tumor received sequential irradiation.
  • The patients with obvious residual disease received chemotherapy during the sequential irradiation.
  • Poor responders, with less than 50% tumor reduction, underwent total laryngectomy.
  • Thirty-four patients were alive (80% of the supraglottic cases and 87.5% of the glottic cases).
  • Local control was achieved in 27 patients (67.5% of the 11 glottic cases and 64.0% of the supraglottic cases).
  • The glottic cohort showed better progression-free survival rates than did the supraglottic cohort (68.8% and 45.0%, respectively; p = 0.019).
  • One patient required tracheostomy 3 months after the completion of the treatment protocol.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Cohort Studies. Disease-Free Survival. Dose Fractionation. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374147.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Mikami Y, Tsukuda M, Kawai S, Kagesato Y, Tanigaki Y, Horiuchi C, Mochimatsu I: [Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1]. Gan To Kagaku Ryoho; 2003 Oct;30(10):1473-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1].
  • Case 1, a 52-year-old man was admitted to our department a diagnosis of supraglottic laryngeal cancer (T3N2cM0) on January 25, 2000.
  • Concurrent chemoradiotherapy consisting of 2 courses of chemotherapy and radiation therapy at 70.2 Gy was administered.
  • After the treatment, a biopsy showed a remaining cancer in the primary lesion.
  • The patient was inoperable and was given radiation therapy of 64.8 Gy.
  • Because of no change of the tumor after radiotherapy, TS-1 was administered at 60 mg x 2/day for 4 weeks followed by a 2-week rest.
  • After TS-1 was administered for 3 courses, a CT showed a remarkable regression of the tumor resulting in a PR for the primary and the neck lesion.
  • The ulcer was an adverse reaction of grade 3, which was improved by conservative therapy.
  • No clear tumor has been observed, and the clinical outcome is considered to be a CR.
  • TS-1 is considered to be an excellent oral anticancer drug in terms of its anti-tumor effect and the patient's QOL.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Head and Neck Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Drug Administration Schedule. Drug Combinations. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Quality of Life. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14584280.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


7. van den Broek GB, Rasch CR, Pameijer FA, Peter E, van den Brekel MW, Tan IB, Schornagel JH, de Bois JA, Zijp LJ, Balm AJ: Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer; 2004 Oct 15;101(8):1809-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the current study, a clinical nomogram was developed to predict local control and overall survival rates for individual patients who will undergo chemoradiation.
  • METHODS: Ninety-two consecutive patients with UICC TNM Stage III/IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and supraglottic larynx were treated with selective-targeted chemoradiation (acronym: RADPLAT).
  • In addition to general factors, the following parameters were analyzed in a multivariable analysis: primary tumor volume, lymph node tumor volume, total tumor volume, lowest involved neck level, comorbidity, pretreatment hemoglobin level, pretreatment weight loss, and unilateral/bilateral intraarterial infusion.
  • Primary tumor volume (hazard ratio [HR], 1.03; P = 0.01) and unilateral infusion (HR, 5.05; P = 0.004) were found to influence local control significantly.
  • Using tumor volume as a continuous variable, an adjusted risk ratio of 1.026 was found, indicating that each 1-cm(3) increase in volume was associated with a 2.6% decrease in probability of local control.
  • Primary tumor volume (HR, 1.01; P = 0.003), comorbidity (American Society of Anesthesiologists [ASA] physical status 1 vs. > 1; HR, 2.47; P = 0.01), lowest involved neck level (HR, 3.45; P = 0.007), and pretreatment weight loss > 10% (HR, 2.04; P = 0.02) were found to be significant predictors of worse overall survival.
  • CONCLUSIONS: Tumor volume was found to play a significant role in predicting local control and overall survival in patients with advanced-stage head and neck carcinoma who were treated with targeted chemoradiation.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Lymph Nodes / pathology. Male. Middle Aged. Models, Biological. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Probability. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386309.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


8. Nayak JV, Cook JR, Molina JT, Branch MP, Branstetter BF 4th, Ferris RL, Myers EN: Primary lymphoma of the larynx: new diagnostic and therapeutic approaches. ORL J Otorhinolaryngol Relat Spec; 2003 Nov-Dec;65(6):321-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the larynx: new diagnostic and therapeutic approaches.
  • Tumors primary in the larynx, when not of squamous cell origin, require special diagnostic and therapeutic attention.
  • This supraglottic tumor was extensively characterized at our institution for morphologic features by microlaryngoscopy, histology, immunocytochemical profiles with flow cytometry, chromosomal aberrations using banded karyotyping and extent of disease via PET-CT imaging.
  • Our detailed analysis distinguished this neoplasm as a new-onset diffuse large B cell laryngeal lymphoma rather than a mucosa-associated lymphoid tissue lymphoma.
  • A rational diagnostic approach guided the combination chemotherapy/immunotherapy treatment strategy instead of traditional localized radiation therapy.
  • These findings highlight the importance of a thorough phenotypic and cytogenetic characterization of head and neck neoplasms, which has implications for downstream diagnostic considerations, interventional strategies and the available therapeutic options.
  • The presence of nonsquamous laryngeal tumors reinforces the dictum to obtain a reliable tissue diagnosis before initiating definitive therapy.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / therapy. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Chromosome Aberrations. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Flow Cytometry. Humans. Immunohistochemistry. Immunophenotyping. Immunotherapy / methods. Karyotyping. Laryngoscopy / methods. Larynx / diagnostic imaging. Larynx / surgery. Male. Middle Aged. Prednisone / therapeutic use. Rituximab. Tomography, Emission-Computed. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14981324.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


9. Gagnon PJ, Galderisi C, Page BR, Holland JM: Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx. Head Neck; 2009 Jun;31(6):829-32
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx.
  • METHODS: This is a case of angiosarcoma developing 5 years after curative therapy for T3N0 squamous cell carcinoma of the supraglottic larynx.
  • Therapy consisted of 3 cycles of induction cisplatin/5-fluorouracil chemotherapy followed by radiotherapy.
  • CT scans assessed the local extent of the tumor and ruled out metastatic disease prior to initiating therapy.
  • RESULTS: Therapy consisted of 4 cycles of paclitaxel chemotherapy.
  • CONCLUSION: This rare therapy-related second malignancy developed after curative larynx-preserving treatment.
  • Paclitaxel was an effective therapy in this setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / therapy. Hemangiosarcoma / etiology. Laryngeal Neoplasms / therapy. Radiotherapy, High-Energy / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. Remission Induction. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc.
  • (PMID = 18853452.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Rodrigo JP, Suárez C, Silver CE, Rinaldo A, Ambrosch P, Fagan JJ, Genden EM, Ferlito A: Transoral laser surgery for supraglottic cancer. Head Neck; 2008 May;30(5):658-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transoral laser surgery for supraglottic cancer.
  • The goal of treatment for supraglottic cancer is to achieve cure and to preserve laryngeal function.
  • Organ preservation strategies include both endoscopic and open surgical approaches as well as radiation and chemotherapy.
  • If complete resection can be achieved, the oncologic results of transoral laser surgery appear to be comparable to those of classic supraglottic laryngectomy.
  • In addition, functional results of transoral laser resection are superior to those of the conventional open approach, in terms of the time required to restore swallowing, tracheotomy rate, incidence of pharyngocutaneous fistulae, and shorter hospital stay.
  • The management of the neck remains of paramount importance, as survival of patients with supraglottic cancer depends more on cervical metastasis than on the primary tumor.
  • However, in selected cases (T1,T2 clinically negative [N0] lateral supraglottic cancers), ipsilateral selective neck dissection could be performed without compromising survival.
  • The authors conclude that with careful selection of patients, laser supraglottic laryngectomy is a suitable, and often the preferred, treatment option for supraglottic cancer.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Laser Therapy / methods
  • [MeSH-minor] Glottis. Humans. Laryngectomy. Laryngoscopy. Neck Dissection. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18327778.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


11. Krishna PD, Malone JP: Isolated adult supraglottic stenosis: surgical treatment and possible etiologies. Am J Otolaryngol; 2006 Sep-Oct;27(5):355-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated adult supraglottic stenosis: surgical treatment and possible etiologies.
  • Isolated supraglottic stenosis in adults without a history of laryngeal injury is a rare and poorly described clinical entity.
  • We report a case of a 61-year-old woman who presented with near total airway obstruction and a diagnosis of an epiglottic mass.
  • She required a tracheotomy for definitive airway control.
  • Initial diagnostic laryngoscopy and biopsies revealed isolated supraglottic stenosis due to fibrosis with acute and chronic inflammation.
  • The patient had a medical history of gastroesophageal reflux disease and hiatal hernia and no history of laryngeal trauma.
  • Transoral supraglottic laryngectomy was required for definitive treatment.
  • Isolated supraglottic stenosis may be seen in children with congenital laryngotracheal anomalies, as a sequelae of prolonged orotracheal intubation or after laryngeal trauma or tumor surgery.
  • Gastroesophageal reflux disease may also contribute to the disease process of isolated supraglottic stenosis.
  • Supraglottic laryngectomy is a feasible treatment option for isolated supraglottic stenosis and may allow for tracheostomy decannulation.
  • [MeSH-minor] Biopsy. Constriction, Pathologic / etiology. Constriction, Pathologic / surgery. Female. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / drug therapy. Humans. Laryngoscopy. Larynx / radiography. Laser Therapy. Middle Aged. Tracheostomy

  • MedlinePlus Health Information. consumer health - Choking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935185.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Laccourreye L, Garcia D, Ménard M, Brasnu D, Laccourreye O, Holsinger FC: Horizontal supraglottic partial laryngectomy for selected squamous carcinoma of the vallecula. Head Neck; 2008 Jun;30(6):756-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Horizontal supraglottic partial laryngectomy for selected squamous carcinoma of the vallecula.
  • BACKGROUND: Our aim was to determine the incidence of local control in patients with selected squamous carcinoma of the vallecula treated with horizontal supraglottic laryngectomy; to analyze the consequences of local recurrence in terms of nodal recurrence, distant metastasis, survival, causes of death, overall local control, and laryngeal preservation; and to identify any clinical factors predictive of these outcomes.
  • According to the 2002 Union Internationale Contre le Cancer (UICC) staging classification system, the tumor was classified as T1, T2, and T3 in 13, 60, and 22 patients, respectively, while disease in 67 patients was considered to be in stages III to IV.
  • All patients underwent a horizontal partial supraglottic partial laryngectomy.
  • An induction chemotherapy regimen was used in 91 patients; postoperative radiation therapy was given for 49 patients.
  • Overall, the main causes of death were as follows: metachronous second primary tumor (47.2% of patients), intercurrent disease (16.7%), distant metastasis (15.3%), local recurrence (6.3%), and nodal recurrence, (4.2%).
  • Nine patients developed a local recurrence; 3 were successfully salvaged.
  • The overall laryngeal preservation rate and local control rate were 89.5% (85/95) and 93.4% (89/95), respectively.
  • CONCLUSIONS: Based on this experience, horizontal partial supraglottic laryngectomy appears to be a valid approach for functional organ-preservation in patients with selected T1-T3 SCC of the vallecula.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Glottis. Laryngeal Neoplasms / therapy. Laryngectomy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Recovery of Function. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18286490.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Jia SS, Wang YY, Pei R, Sun J: [Pathological feature and management of occult lymphatic metastasis in supraglottic carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Feb;40(2):103-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathological feature and management of occult lymphatic metastasis in supraglottic carcinoma].
  • OBJECTIVE: To study the pathologic feature and management methods of occult lymphatic metastasis in patients with supraglottic carcinoma.
  • (1) Supraglottic squamous cell carcinoma;.
  • (3) no preoperative radiotherapy and (or) chemotherapy.
  • Two years survival rates was 86.7% (26/30) without tumor.
  • CONCLUSION: Occult metastasis rate of supraglottic carcinoma is as high as 30%.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Laryngeal Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429726.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


14. Powitzky R, Powitzky ES, Garcia R: Liposarcoma of the larynx. Ann Otol Rhinol Laryngol; 2007 Jun;116(6):418-24
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The objective was to review the presentation, diagnosis, treatment, and prognosis of patients with laryngeal liposarcoma (LLS).
  • The most common location of the tumor is the supraglottis, and the presenting complaints are similar to those of other laryngeal neoplasms.
  • Because the histologic changes are frequently subtle, LLS can be easily mistaken for a benign tumor.
  • As a result, the diagnosis requires a high index of suspicion and diligence in examining biopsy specimens.
  • Computed tomography and magnetic resonance imaging can assist in the diagnosis and surgical approach.
  • Genetic and immunostaining analysis techniques may also prove to have valuable prognostic, diagnostic, and therapeutic implications for this disease.
  • Wide surgical excision is the mainstay of treatment.
  • The use of radiotherapy and chemotherapy in treating this cancer remains experimental, but might be considered on a case-to-case basis for palliation or to treat aggressive variants of the disease.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Liposarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672243.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, Van Echo D, Ord R: The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol; 2004 Dec;31(6 Suppl 18):2-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Concurrent chemotherapy and radiation has improved the outcome for patients presenting with locally advanced squamous cell carcinomas of the head and neck (SCCHN).
  • These improvements have come at a cost of increased treatment-related toxicities.
  • Treatment consisted of daily RT delivered to 70.2 Gy (1.8 Gy/fx) with amifostine 500 mg IV (<1 hour before RT), and concurrent weekly carboplatin (100 mg/m2) and paclitaxel (40 mg/m2).
  • Tumor characteristics based on histology were: primary cancers of the oropharynx (55.6%); supraglottic larynx (16.7%); hypopharynx (16.7%); oral cavity (5.6%); and unknown primaries (5.6%).
  • Toxicities were measured weekly during treatment and at each follow-up visit.
  • Disease response to therapy was determined 2 months after completion of therapy.
  • Eighty-four percent completed the prescribed radiation treatment, and 84% of patients received more than six cycles of chemotherapy.
  • The median number of missed chemotherapy cycles was 1.5 (range, 0 to 5 cycles).
  • Grade 3 toxicities associated with therapy were: mucositis and dysphagia (40% of patients each), dehydration (27%), xerostomia (20%), and dermatitis (20%); 53% of patients experienced grade 3 leukopenia, while grade 3/4 neutropenia developed in 20%/13%.
  • Forty percent of patients completed RT without unscheduled treatment breaks secondary to treatment-related toxicity.
  • Median treatment-break time was 5 days (range, 0 to 20 days).
  • Weekly carboplatin and paclitaxel administered concurrently with definitive RT and daily amifostine is well tolerated, with over 85% of patients completing therapy with acceptable toxicity.
  • The addition of amifostine appears to decrease treatment-related toxicity without impacting efficacy.
  • [MeSH-major] Amifostine / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carboplatin / adverse effects. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Mucous Membrane / drug effects. Paclitaxel / adverse effects
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726515.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Monje ML, Ramakrishna NR, Young G, Drappatz J, Doherty LM, Wen PY, Kesari S: Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. J Neurooncol; 2007 Sep;84(2):179-83
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Our patient developed a cerebellar high-grade glioma 9 years after treatment for a stage IV (T4N0M0) supraglottic laryngeal squamous cell carcinoma with cisplatinum and fluorouracil chemotherapy, and subsequently focal head and neck radiotherapy.
  • Patient was treated with radiation and concurrent temozolomide (only partially due to toxicity) and was stable for 1 year without further adjuvant treatment.
  • Subsequently the tumor recurred and the patient had a dramatic and durable response to standard 5 day dosing of adjuvant temozolomide.
  • CONCLUSION: High-grade gliomas are a late complication of radiation to the central nervous system and may respond to chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cerebellar Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy. Neoplasms, Radiation-Induced / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / radiotherapy. Diagnosis, Differential. Female. Humans. Laryngeal Neoplasms / radiotherapy. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / pathology. Positron-Emission Tomography. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2006 May;78(1):55-7 [16314941.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1431-8 [10329596.001]
  • [Cites] Br J Radiol. 2006 Aug;79(944):652-8 [16641420.001]
  • [Cites] Radiol Clin North Am. 2005 Jan;43(1):35-47 [15693646.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):221-5 [17029014.001]
  • [Cites] Int J Radiat Biol. 2004 May;80(5):327-37 [15223765.001]
  • [Cites] Int J Cancer. 2001 Jun 20;96(3):191-7 [11410888.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurooncol. 1989 Nov;7(4):339-44 [2555454.001]
  • (PMID = 17332945.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


17. Paulino AC, Simon JH, Zhen W, Wen BC: Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys; 2000 Dec 1;48(5):1489-95
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To examine the long-term effects of treatment in children receiving radiotherapy for head and neck rhabdomyosarcoma.
  • There were 11 males and 6 females, with a median age of 5.7 years (range 2.2-11.6) at the time of radiotherapy.
  • Tumor location was orbit in 6 patients, infratemporal fossa in 4, paranasal sinuses in 2, and supraglottic larynx in 2; the nasopharynx, pterygopalatine fossa, and parotid gland were sites for the remaining children.
  • The Intergroup Rhabdomyosarcoma Study (IRS) Group was I in 2, II in 3, and III in 11 children; 1 patient had a recurrent tumor after surgery alone.
  • Radiotherapy volume was the primary tumor or tumor bed in 13, tumor and whole brain in 3, and tumor and craniospinal axis in 1.
  • All but 1 were treated with 150-200-cGy fractions; 1 patient received 250-cGy fractions for a tumor in the larynx.
  • Chemotherapy was vincristine (V), actinomycin-D (A), and cyclophosphamide (C) in 10 patients, VAC + adriamycin in 2, VA in 1, VA + ifosfamide in 1, VC + adriamycin in 1, and none in 2.
  • One patient had salvage chemotherapy consisting of cisplatin and etoposide.
  • Median follow-up time was 20 years (range 7.5-33).
  • RESULTS: Late effects of treatment were seen in all patients and included facial growth retardation in 11, neuroendocrine dysfunction in 9, visual/orbital problems in 9, dental abnormalities in 7, hearing loss in 6, and hypothyroidism in 3.
  • While neuroendocrine, thyroid, dental, and cognitive sequelae were primarily attributed to radiotherapy, hearing loss was thought to be a direct result of tumor destruction and, in 1 case, cisplatin chemotherapy.
  • CONCLUSION: Late effects of treatment in children receiving radiotherapy for head and neck rhabdomyosarcoma are frequent.
  • Late toxicity of treatment beyond 10 years is not as frequent as those occurring within 10 years of therapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cochlea / drug effects. Cochlea / radiation effects. Cognition / radiation effects. Combined Modality Therapy. Cranial Irradiation / adverse effects. Dentition. Educational Status. Facial Asymmetry / etiology. Female. Follow-Up Studies. Growth / radiation effects. Growth Hormone / deficiency. Growth Hormone / radiation effects. Humans. Hypothalamus / radiation effects. Male. Orbital Neoplasms / radiotherapy. Pituitary Gland / radiation effects. Radiotherapy Dosage. Time Factors. Vision Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11121653.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


18. Papadas TA, Alexopoulos EC, Mallis A, Jelastopulu E, Mastronikolis NS, Goumas P: Survival after laryngectomy: a review of 133 patients with laryngeal carcinoma. Eur Arch Otorhinolaryngol; 2010 Jul;267(7):1095-101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after laryngectomy: a review of 133 patients with laryngeal carcinoma.
  • Survival trends in survival for laryngeal cancer in Europe are varied.
  • The aim of this study was to assess the factors influencing survival in patients with laryngeal cancer in our region.
  • A total of 128 male and 5 female patients with larynx cancer (91 glottic and 42 supraglottic) were treated at Patras University Hospital between March 1992 and August 2004.
  • All patients underwent laryngectomy with extension of the procedure where appropriate.
  • Also, a total of 45 patients received adjuvant therapy (either chemotherapy or radiotherapy).
  • Significant prognostic factors for OS included patient age, advanced staging, heavy alcohol use and poor tumor differentiation while for DFS affected mainly by poor tumor differentiation.
  • We conclude that the disease stage at presentation, tumor grade and alcohol consumption prove to be important predictors for the OS as well as the DFS in our series.
  • [MeSH-major] Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / surgery. Laryngectomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Combined Modality Therapy. Female. Greece / epidemiology. Humans. Male. Middle Aged. Neoplasm Staging. Occupations. Proportional Hazards Models. Risk Factors. Smoking / adverse effects. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1996 Jul-Aug;16(4B):2257-67 [8694553.001]
  • [Cites] Neoplasma. 2005;52(6):483-8 [16284693.001]
  • [Cites] Cancer Treat Rev. 2006 Nov;32(7):504-15 [16920269.001]
  • [Cites] J Epidemiol Community Health. 1988 Dec;42(4):350-4 [3256577.001]
  • [Cites] Cancer. 2004 May 1;100(9):1786-92 [15112257.001]
  • [Cites] Laryngoscope. 2008 Jun;118(6):1003-13 [18388773.001]
  • [Cites] Eur J Cancer Prev. 2008 Apr;17(2):116-24 [18287868.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Laryngoscope. 2006 Sep;116(9 Pt 2 Suppl 111):1-13 [16946667.001]
  • [Cites] Otolaryngol Pol. 2008;62(6):691-4 [19205513.001]
  • [Cites] J Otolaryngol. 2000 Apr;29(2):67-77 [10819103.001]
  • [Cites] J Epidemiol Community Health. 1985 Jun;39(2):165-8 [4009100.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):412-21; discussion 421-2 [14501507.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Laryngoscope. 2004 Aug;114(8):1438-46 [15280724.001]
  • [Cites] Head Neck. 2004 Feb;26(2):127-35 [14762881.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):773-83 [17714991.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1172-80 [11483326.001]
  • [Cites] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2007 May;21(10):466-7 [17650820.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Oct;107(4):577-82 [1437190.001]
  • [Cites] Laryngoscope. 2000 Mar;110(3 Pt 1):408-11 [10718428.001]
  • [Cites] Acta Otorhinolaryngol Ital. 1999 Dec;19(6):325-41 [10875156.001]
  • [Cites] Eur J Cancer Prev. 2004 Jun;13(3):165-72 [15167214.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Jul;117(7):774-8 [1863444.001]
  • [Cites] Br J Ind Med. 1992 Dec;49(12):837-44 [1472441.001]
  • (PMID = 19921233.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Dirix P, Abbeel S, Vanstraelen B, Hermans R, Nuyts S: Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):385-92
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Consecutive patients, treated with radiotherapy (70-72 Gy) and concomitant chemotherapy (cisplatinum 100 mg/m(2) every 3 weeks) between 2004 and 2007, were examined.
  • The volume of the middle pharyngeal constrictor muscle receiving > or =50 Gy (p = 0.04), the mean dose to this structure (p = 0.02) and to the supraglottic larynx (p = 0.04) were significantly associated with late swallowing problems at univariate analysis, along with tumor localization (p = 0.008), T-classification (p = 0.02), and pretreatment swallowing problems (p = 0.01).
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Deglutition Disorders / etiology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Deglutition / drug effects. Deglutition / radiation effects. Dose-Response Relationship, Radiation. Female. Humans. Larynx / drug effects. Larynx / radiation effects. Male. Middle Aged. Pharyngeal Muscles / drug effects. Pharyngeal Muscles / radiation effects. Quality of Life. Radiation Injuries / complications


20. Hartl DM, Landry G, Hans S, Marandas P, Brasnu DF: Organ preservation surgery for laryngeal squamous cell carcinoma: low incidence of thyroid cartilage invasion. Laryngoscope; 2010 Jun;120(6):1173-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation surgery for laryngeal squamous cell carcinoma: low incidence of thyroid cartilage invasion.
  • OBJECTIVES/HYPOTHESIS: Determine the incidence and risk factors for thyroid cartilage invasion in early and midstage laryngeal cancer.
  • Preoperative laser, radiation therapy, or chemotherapy were excluded.
  • Tumor stage, anterior commissure involvement, vocal fold (VF) mobility, computed tomography (CT) scan, and pathological cartilage status were recorded.
  • RESULTS: Three hundred fifty-eight patients were treated for tumors staged cT1 (32%), cT2 (53%), and cT3 (15%) by vertical (26%), supracricoid (62%), or supraglottic partial laryngectomy (12%).
  • [MeSH-major] Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Laryngectomy / methods. Thyroid Cartilage / pathology. Thyroid Cartilage / surgery
  • [MeSH-minor] Female. Humans. Incidence. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20513035.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Franzen A, Kurrer MO: [Malignant lymphoma of the larynx: a case report and review of the literature]. Laryngorhinootologie; 2000 Oct;79(10):579-83
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Das maligne Lymphom des Larynx: Fallbericht und Literaturübersicht.
  • BACKGROUND: Malignant lymphoma of the larynx are rare tumors and represent less than 1% of primary malignant laryngeal tumors.
  • Clinical presentation, diagnostic approach, staging and differential diagnosis as well as therapy and prognosis are discussed in relation to the available literature.
  • CONCLUSIONS: Lymphomas primary to the larynx are non-Hodgkin-lymphomas and are predominantly located in the supraglottic larynx.
  • Indirect laryngoscopy reveals a globoid submucosal faintly pink tumor mass.
  • The diagnosis rests on histological examination of a biopsy specimen.
  • Benign tumors, squamous cell carcinoma and other lymphoproliferative diseases have to be excluded from the differential diagnosis.
  • Extensive tumor staging is necessary before radiotherapy or chemotherapy.
  • Prognosis is good in the most often localized laryngeal non-Hodgkin-lymphomas (stage IE and IIE) and generalization is rare.
  • Hence, supraglottic submucosal laryngeal tumors can represent non-Hodgkin-lymphomas.
  • Biopsy and subsequent histological examination are essential for correct diagnosis.
  • [MeSH-major] Laryngeal Neoplasms. Lymphoma, B-Cell
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Laryngoscopy. Larynx / pathology. Male. Prednisone / therapeutic use. Prognosis. Radiotherapy Dosage. Terminology as Topic. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11089205.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


22. Alagić-Smailbegović J, Kapidzić A, Sutalo K, Resić M, Hadzić E: Incidence of malignant tumors of larynx and their treatment. Bosn J Basic Med Sci; 2004 Oct;4(4):25-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of malignant tumors of larynx and their treatment.
  • According to the tumor site, TNM classification, operative procedure and postoperative treatment we found the following: Over the last 5 years 156 patients underwent surgical treatment--143 (91,6%) male and 23 (8.4%) female.
  • The rest of the patients underwent total laryngeoctomy with unilateral or bilateral dissection (16%) chordectomy (4%), supraglottic laryngectomy (3%), hemilaryngectomy (2%) and hemilaryngectomy with dissection (1%) All patients were postoperatively irradiated and chemotherapy was combined with irradiation only in younger patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15628992.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


23. Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Mancuso AA: Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck; 2003 Jul;25(7):535-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
  • PURPOSE: To analyze parameters that may influence the likelihood of local control after definitive radiotherapy for head and neck cancer.
  • METHODS: Between April 1980 and January 2000, 404 patients were treated with definitive RT alone (358 patients) or combined with adjuvant chemotherapy (46 patients) at our institution and were followed up for 0.25 to 20.25 years (median, 3.5 years.
  • All patients had the primary tumor volume calculated on pretreatment CT.
  • Parameters evaluated in multivariate analyses of these end points included primary site, T stage, primary tumor volume, N stage, histologic differentiation, fractionation schedule, adjuvant chemotherapy, and gender.
  • RESULTS: The rates of local control and local control without a severe late complication after RT were significantly influenced by primary tumor volume for patients with cancer of the supraglottic larynx and true vocal cord.
  • In contrast, the rates of local control and local control without severe complications for patients with tumors of the oropharynx and hypopharynx were less influenced by tumor volume.
  • Multivariate analyses stratified by primary site revealed that tumor volume significantly influenced local control for patients with cancers of the supraglottis (p =.0220) and glottis (p =.0042) but not for those with lesions of the tonsillar fossa/posterior tonsillar pillar (p =.0892), base of tongue (p =.9493), anterior tonsillar pillar/soft palate (p =.5909), and hypopharynx (p =.2282).
  • Primary tumor volume also significantly influences the probability of local control in cancers of the supraglottis and glottis.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Radiotherapy / adverse effects. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc. Head Neck 25: 535-542, 2003
  • (PMID = 12808656.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Studer G, Peponi E, Kloeck S, Dossenbach T, Huber G, Glanzmann C: Surviving hypopharynx-larynx carcinoma in the era of IMRT. Int J Radiat Oncol Biol Phys; 2010 Aug 1;77(5):1391-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Outcome in locoregionally advanced laryngeal carcinoma and hypopharyngeal carcinoma after conventional radiation techniques is known for modest disease control and considerable late toxicity.
  • METHODS AND MATERIALS: Between March 2002 and December 2008, 65 hypopharyngeal, 31 supraglottic, and 27 locoregionally advanced glottic tumor patients underwent definitive IMRT (with simultaneous chemotherapy in 86%).
  • Treatment (2.0-2.2 Gy per fraction, 66-72.6 Gy) followed a prospectively defined protocol.
  • If the boost volume included more than half of the larynx or a substantial part of the pharynx, dose was limited to 2.0 Gy per fraction.
  • Considering the treatment tolerance, a careful increase in dose in our patients seems possible.
  • [MeSH-major] Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Enteral Nutrition. Female. Follow-Up Studies. Glottis. Humans. Laryngectomy. Male. Middle Aged. Radiotherapy Dosage. Salvage Therapy / methods. Survival Rate. Tracheostomy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20056352.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Tian WD, Zeng ZY, Chen FJ, Wu GH, Guo ZM, Zhang Q: [Treatment and prognosis of stage III-IV laryngeal squamous cell carcinoma]. Ai Zheng; 2006 Jan;25(1):80-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of stage III-IV laryngeal squamous cell carcinoma].
  • BACKGROUND & OBJECTIVE: Laryngeal squamous cell carcinoma (LSCC) is a common malignancy of the head and neck.
  • Stage I-II LSCC patients have a favorable prognosis after operation or radiotherapy, but the curative effect and prognosis of stage III-IV LSCC are not satisfying, and its treatment is also controversial.
  • This study was to summarize our experience in treating stage III-IV LSCC patients, evaluate the treatment results, and seek more reasonable therapeutic modality.
  • Of the 202 patients, 64 received surgery alone, 83 received surgery and preoperative or postoperative radiotherapy, 41 received radiotherapy, and 14 received chemotherapy.
  • RESULTS: The 5- and 10-year overall survival rates of the 202 patients was (42.12+/-3.62)% and (33.20+/-4.32)%, and the median survival time was 48.5 months.
  • The 5-year survival rates were 61.07% in glottic carcinoma group and 26.07% in supraglottic carcinoma group, and were 53.41% in surgery alone group, 51.04% in surgery plus radiotherapy group, 18.33% in radiotherapy group and 7.14% in chemotherapy group.
  • Eleven patients had tumor relapsed after total laryngectomy within 5 years.
  • CONCLUSIONS: Surgery, especially total laryngectomy, is the major treatment modality for stage III-IV LSCC.
  • Postoperative radiotherapy may be preformed on the patients with suspect of tumor residue or positive margin.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / surgery. Laryngectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405756.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Ferlito A, Silver CE, Rinaldo A, Smith RV: Surgical treatment of the neck in cancer of the larynx. ORL J Otorhinolaryngol Relat Spec; 2000 Jul-Aug;62(4):217-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of the neck in cancer of the larynx.
  • Current concepts in management of the clinically negative and clinically positive neck in laryngeal cancer are reviewed.
  • The surgeon should be aware of the relatively high incidence of micrometastases in patients with laryngeal cancer to establish optimal treatment approaches.
  • Elective treatment of the neck is recommended for supraglottic tumors staged T2 or higher, and glottic or subglottic tumors staged T3 or higher.
  • The neck may be treated electively by either surgery or irradiation, but irradiation is best reserved for cases where that modality is employed for the primary tumor.
  • Elective neck dissection provides important information for prognostic purposes and therapeutic decisions, by establishing the presence, number, location and nature of occult lymph node metastases.
  • The selective lateral neck dissection (levels II, III and IV), unilateral or bilateral, is the procedure of choice for elective treatment.
  • Sentinel lymph node biopsy may fail to detect tumor on frozen section examination or may not reveal 'skip' metastases.
  • More advanced disease has been treated in this manner often in association with adjuvant chemotherapy and/or irradiation.
  • While the benefit of adjuvant treatment is difficult to assess, it appears most useful in cases with extranodal spread of disease, a factor associated with the worst prognosis.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Lymph Node Excision. Neck / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10859523.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 114
  •  go-up   go-down


27. Abo H, Tsukuda M, Matsuda H, Horiuchi C, Taguchi T, Watanabe M, Niho T: [Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1707-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx].
  • We report two successful remnant and recurrent cases of head and neck cancer treated with S-1.
  • Case 1, a 52-year-old man, was diagnosed as supraglottic laryngeal carcinoma (T3N2cM0, squamous cell carcinoma: SCC) on January 25, 2000, and concurrent chemoradiotherapy (CCRT) was applied.
  • After the treatment, a remnant tumor in the larynx was found by biopsy.
  • Pulmonary metastasis was detected by chest CT on June 14, 2001, and the administration of S-1 was started.
  • The administration of S-1 is still continuing and remnant tumors have not been found.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838032.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


28. Galli J, De Corso E, Volante M, Almadori G, Paludetti G: Postlaryngectomy pharyngocutaneous fistula: incidence, predisposing factors, and therapy. Otolaryngol Head Neck Surg; 2005 Nov;133(5):689-94
MedlinePlus Health Information. consumer health - Throat Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postlaryngectomy pharyngocutaneous fistula: incidence, predisposing factors, and therapy.
  • Systemic diseases, previous radiotherapy, supraglottic origin of tumor, and concurrent radical neck dissection were significantly associated with PCF.
  • [MeSH-major] Cutaneous Fistula / epidemiology. Cutaneous Fistula / therapy. Laryngectomy / adverse effects. Pharyngeal Diseases / epidemiology. Pharyngeal Diseases / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Combined Modality Therapy. Confidence Intervals. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Incidence. Italy. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Logistic Models. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Postoperative Complications / diagnosis. Postoperative Complications / therapy. Reoperation. Retrospective Studies. Risk Factors. Severity of Illness Index. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274794.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Conti-Freitas LC, Foss-Freitas MC, Mamede RC, Foss NT: Effect of BCG stimulus on proinflammatory cytokine production in laryngeal cancer. Cancer Immunol Immunother; 2009 Jan;58(1):25-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of BCG stimulus on proinflammatory cytokine production in laryngeal cancer.
  • BACKGROUND: Evaluate the production of TNF and IL-6 in the supernatant of peripheral blood mononuclear cell (PBMC) cultures of patients with supraglottic laryngeal cancer before and after surgical treatment.
  • Fourteen patients with advanced supraglottic laryngeal cancer were studied.
  • CONCLUSION: BCG is able to modulate the immune response of patients with advanced supraglottic laryngeal cancer in vitro, increasing the secretion of TNF and IL-6 by macrophages during the postoperative period.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma / drug therapy. Cytokines / biosynthesis. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Inflammation. Interleukin-6 / biosynthesis. Interleukin-6 / blood. Interleukin-6 / immunology. Male. Middle Aged. Neoplasm Staging. Smoking. Tumor Necrosis Factor-alpha / biosynthesis. Tumor Necrosis Factor-alpha / blood. Tumor Necrosis Factor-alpha / immunology

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18421458.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Cytokines; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down






Advertisement